Citations to this article

New and emerging HDAC inhibitors for cancer treatment
Alison C. West, Ricky W. Johnstone
Alison C. West, Ricky W. Johnstone
Published January 2, 2014
Citation Information: J Clin Invest. 2014;124(1):30-39. https://doi.org/10.1172/JCI69738.
View: Text | PDF
Review Series Article has an altmetric score of 31

New and emerging HDAC inhibitors for cancer treatment

Abstract

Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci. The identification of these enzymes and their partner proteins has driven the rapid development of small-molecule inhibitors that target the cancer epigenome. Herein, we discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis. We examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.

Authors

Alison C. West, Ricky W. Johnstone

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2009 Total
Citations: 25 32 47 59 68 56 75 72 95 82 61 22 1 695
Citation information

Citations to this article in year 2023 (47)

Title and authors Publication Year
Assessment of HDAC Inhibitor-Induced Endoplasmic Reticulum (ER) Stress.
Halilovic M, Marx-Blümel L, Marx C, Buder K, Beck JF, Sonnemann J 		Methods in molecular biology (Clifton, N.J.) 2023
Expression and Function of StAR in Cancerous and Non-Cancerous Human and Mouse Breast Tissues: New Insights into Diagnosis and Treatment of Hormone-Sensitive Breast Cancer
Manna PR, Ramachandran S, Pradeepkiran JA, Molehin D, Castro-Piedras I, Pruitt K, Ganapathy V, Reddy PH 		International journal of molecular sciences 2023
Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy
Parab A, Kumar Bhatt L, Omri A 		Biomedicines 2023
Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways
Lim JS, Kyung SY, Jeon Y, Kim IS, Kwak JH, Kim HS 		Oncology reports 2023
Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study
Li XY, Han XW, Huang K, Zhang YT, Xu HG, Zhou DH, Xu LH, Fang JP 		Frontiers in Medicine 2023
Heterocycles in Breast Cancer Treatment: The Use of Pyrazole Derivatives.
Ardevines S, Marqués-López E, Herrera RP 		Current medicinal chemistry 2023
Circular RNA circ_0000741/miR-379-5p/TRIM14 signaling axis promotes HDAC inhibitor (SAHA) tolerance in glioblastoma.
Meng L, Wang Y, Tu Q, Zhu Y, Dai X, Yang J 		Metabolic Brain Disease 2023
Regulation of SUMOylation on RNA metabolism in cancers
Cao Y, Huang C, Zhao X, Yu J 		Frontiers in Molecular Biosciences 2023
Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer.
Rezaeian AH, Phan LM, Zhou X, Wei W, Inuzuka H 		Neoplasia (New York, N.Y.) 2023
HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non–small cell lung cancer
Eichner LJ, Curtis SD, Brun SN, McGuire CK, Gushterova I, Baumgart JT, Trefts E, Ross DS, Rymoff TJ, Shaw RJ 		Science Advances 2023
Role of epigenetics in OSCC: an understanding above genetics.
Vatsa PP, Jindal Y, Bhadwalkar J, Chamoli A, Upadhyay V, Mandoli A 		Medical Oncology 2023
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.
Elbezanti WO, Challagundla KB, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK 		Pharmaceuticals (Basel, Switzerland) 2023
The landscape of cryptic antisense transcription in human cancers reveals an oncogenic noncoding RNA in lung cancer
Zhao Z, Chen Y, Cheng X, Huang L, Wen H, Xu Q, Zhou X, Zhang X, Chen J, Ni T 		Science Advances 2023
Metabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and function
Lei I, Huang W, Noly PE, Naik S, Ghali M, Liu L, Pagani FD, Ela AA, Pober JS, Pitt B, Platt JL, Cascalho M, Wang Z, Chen YE, Mortensen RM, Tang PC 		Science Translational Medicine 2023
Macrocyclic Octapeptide Binding and Inferences on Protein Substrate Binding to Histone Deacetylase 6
Watson PR, Gupta S, Hosseinzadeh P, Brown BP, Baker D, Christianson DW 		ACS chemical biology 2023
Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
Peng X, Yu Z, Surineni G, Deng B, Zhang M, Li C, Sun Z, Pan W, Liu Y, Liu S, Yu B, Chen J 		Journal of Enzyme Inhibition and Medicinal Chemistry 2023
Histone Deacetylase 1 Inhibition by Peptides Containing a DNA Damage-Induced, Nonenzymatic, Histone Covalent Modification.
Jacinto MP, Greenberg MM 		Biochemistry 2023
The Role of Histone Deacetylases in Acute Lung Injury—Friend or Foe
Luo G, Liu B, Fu T, Liu Y, Li B, Li N, Geng Q 		International journal of molecular sciences 2023
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma
Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, Pérez-Carreón JI, Camacho J 		World Journal of Gastroenterology 2023
Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone.
Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Akiyama T, Kojima N, Toda Y, Sato C, Fukushima S, Yoshida A, Kawai A, Kondo T 		Human Cell 2023
Sirtuin Inhibitor Cambinol Induces Cell Differentiation and Differently Interferes with SIRT1 and 2 at the Substrate Binding Site
Giordano D, Scafuri B, De Masi L, Capasso L, Maresca V, Altucci L, Nebbioso A, Facchiano A, Bontempo P 		Biomedicines 2023
Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
Drzewiecka M, Gajos-Michniewicz A, Hoser G, Jaśniak D, Barszczewska-Pietraszek G, Sitarek P, Czarny P, Piekarski J, Radek M, Czyż M, Skorski T, Śliwiński T 		Genes & development 2023
The Synergistic Antitumor Effect of Decitabine and Vorinostat Combination on HepG2 Human Hepatocellular Carcinoma Cell Line via Epigenetic Modulation of Autophagy-Apoptosis Molecular Crosstalk.
Salama BM, Helmy MW, Fouad H, Shamaa MM, Houssen ME 		Current issues in molecular biology 2023
HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells
Lyu H, Hou D, Liu H, Ruan S, Tan C, Wu J, Hicks C, Liu B 		npj Precision Oncology 2023
Inhibition of EZH2 alleviates SAHA-induced senescence-associated secretion phenotype in small cell lung cancer cells.
Kong SH, Ma L, Yuan Q, Liu X, Han Y, Xiang W, Liu DX, Zhang Y, Lu J 		Cell Death Discovery 2023
Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics.
Bahia RK, Hao X, Hassam R, Cseh O, Bozek DA, Luchman HA, Weiss S 		Nature Communications 2023
Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells.
Tsai FL, Huang HL, Lai MJ, Liou JP, Pan SL, Yang CR 		International journal of molecular sciences 2023
CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells.
Liu X, Tian F, Cui J, Gong L, Xiang L, Fan B, Liu S, Zhan J, Zhou Y, Jiang B, Wang M, Sun G, Gong Y, Zou Y 		Oncogene 2023
Quatramer™ encapsulation of dual‐targeted PI3‐Kδ/HDAC6 inhibitor, HSB‐510, suppresses growth of breast cancer
Tiwari S, Liu S, Anees M, Mehrotra N, Thakur A, Tawa GJ, Grewal G, Stone R, Kharbanda S, Singh H 		Bioengineering & Translational Medicine 2023
Enhancing Transcriptional Reprogramming of Mesenchymal Glioblastoma with Grainyhead-like 2 and HDAC Inhibitors Leads to Apoptosis and Cell-Cycle Dysregulation
Kotian S, Carnes RM, Stern JL 		Genes & development 2023
Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases
Merati A, Kotian S, Acton A, Placzek W, Smithberger E, Shelton AK, Miller CR, Stern JL 		International journal of molecular sciences 2023
Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells
Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, Czarny P, Kobrzycka A, Wieczorek M, Radek M, Szemraj J, Skorski T, Śliwiński T 		Journal of Personalized Medicine 2023
Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma
Yu Z, Ding M, Cai Y, Lu T, Chen X, Zhou X, Wang X 		BMC Cancer 2023
Immune-epigenetic crosstalk in haematological malignancies
Wong H, Sugimura R 		Frontiers in Cell and Developmental Biology 2023
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer
Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M 		Molecular Cancer 2023
Untargeted LC-MS/MS Metabolomics Study of HO-AAVPA and VPA on Breast Cancer Cell Lines
Estrada-Pérez AR, García-Vázquez JB, Mendoza-Figueroa HL, Rosales-Hernández MC, Fernández-Pomares C, Correa-Basurto J 		International journal of molecular sciences 2023
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida HQ, Abdulla A, Marzooqi SA, Hashem S, Macha MA, Akil AS, Bhat AA 		Translational oncology 2023
Epigenetic Dysregulation and Its Correlation with the Steroidogenic Machinery Impacting Breast Pathogenesis: Data Mining and Molecular Insights into Therapeutics
Manna PR, Yang S, Reddy PH 		International journal of molecular sciences 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Murphy T, Mason JM, Leber B, Bray MR, Chan SM, Gupta V, Khalaf D, Maze D, McNamara CJ, Schimmer AD, Schuh AC, Sibai H, Trus M, Valiquette D, Martin K, Nguyen L, Li X, Mak TW, Minden MD, Yee KWL 		Leukemia 2023
Exploring the Molecular Underpinnings of Cancer-Causing Oncohistone Mutants Using Yeast as a Model
Zhang X, Fawwal DV, Spangle JM, Corbett AH, Jones CY 		Journal of Fungi 2023
A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors
Drakontaeidi A, Pontiki E 		Pharmaceuticals 2023
Peptidomics Unveils Distinct Acetylation Patterns of Histone and Annexin A1 in Differentiated Thyroid Cancer
Coelho M, Capela J, Mendes VM, Pacheco J, Fernandes MS, Amendoeira I, Jones JG, Raposo L, Manadas B 		International journal of molecular sciences 2023
Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell–cell fusion
Nakatake M, Kurosaki H, Nakamura T 		Cancer Science 2023
P53 together with ferroptosis: a promising strategy leaving cancer cells without escape.
Zhan J, Wang J, Liang Y, Zeng X, Li E, Wang H 		Acta Biochimica et Biophysica Sinica 2023
A narrative review of the role of HDAC6 in idiopathic pulmonary fibrosis
Yu H, Liu S, Wang S, Gu X 		Journal of Thoracic Disease 2023
The role of proteasomes in tumorigenesis
Zhou X, Xu R, Wu Y, Zhou L, Xiang T 		Genes & Diseases 2023
Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma
Lu Y, Yang J, Zhu J, Shu Y, Zou X, Ruan Q, Luo S, Wang Y, Wen J 		Journal of Oncology 2023

Advertisement